δ Opioid Receptor/DOR

δ Opioid Receptor/DOR Related Products (24):

By Type:	Pan (9) Selective (3)
By Effects:	Inhibitor (1) Agonists (16) Antagonists (5)

Cat. No.	Product Name	Effect	Purity

HY-P1502

β-Endorphin, human	Agonist
β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.

HY-G0021

N-Desmethylclozapine	Agonist	99.66%
N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC₅₀=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist.

HY-P1335A

CTAP TFA	Antagonist	99.56%
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.

HY-P1334

DPDPE	Agonist	98.64%
DPDPE, an opioid peptide, is a selective δ-opioid receptor (DOR) agonist with anticonvulsant effects.

HY-124754

Navacaprant	Inhibitor	99.97%
Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC₅₀ values of 0.8 nM, 110 nM, and 6500 nM, respectively. Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy.

HY-161405

NPFF1-R antagonist 1
NPFF1-R antagonist 1 (compound 8b), a piperidine analogue, is a potent neuropeptide FF (NPFF) receptor antagonist. NPFF1-R antagonist 1 is 15-fold selective for the NPFF1-R subtype, with K_i values of 211 nM and 3270 nM for NPFF1-R and NPFF2-R, respectively.

HY-P1467A

[Met5]-Enkephalin, amide TFA	Agonist
[Met5]-Enkephalin, amide TFA is an agonist for δ opioid receptors as well as putative ζ (zeta) opioid receptors.

HY-P0098

[D-Ala2]leucine-enkephalin	Agonist	98.64%
[D-Ala2]leucine-enkephalin, a delta opioid agonist, is a degradation resistant long-acting Leu-enkephalin.

HY-P1013A

Deltorphin 2 TFA	Agonist	99.88%
Deltorphin 2 TFA is a selective peptide agonist for the δ opioid receptor.

HY-13044

ADL-5859 hydrochloride	Agonist	99.77%
ADL-5859 hydrochloride (compound 20) is a selective and orally active δ opioid receptor (DOR) agonist with an K_i and an EC₅₀ value of 0.84 and 20 nM, respectively. ADL-5859 hydrochloride also shows inhibitory activity to hERG channel with an IC₅₀ value of 78 μM. ADL-5859 hydrochloride can be used for the research of pain.

HY-P1334A

DPDPE TFA	Agonist	99.94%
DPDPE TFA, an opioid peptide, is a selective δ-opioid receptor (DOR) agonist with anticonvulsant effects.

HY-P1866A

β-Endorphin, equine TFA	Agonist
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioid receptors. β-Endorphin, equine TFA has analgesic properties.

HY-114072

J-113397	Antagonist	≥99.0%
J-113397 is the first potent and selective nonpeptidyl ORL1 receptor antagonist (K_i: cloned human ORL1=1.8 nM) without any agonistic effects on other opioid receptors.

HY-P4053

Dalargin	Agonist	99.52%
Dalargin is a potent δ-opioid receptor agonist. Dalargin mitigates Gentamicin (HY-A0276)-induced cell death. Dalargin shows nephroprotective effects on Gentamicin-induced kidney injury. Dalargin shows antiulcer activity.

HY-P1335

CTAP	Antagonist
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.

HY-151811

NAQ	Agonist
NAQ is a potent and selective μ opioid receptor partial agonist, with a K_i of 0.55 nM. NAQ shows selectivity for Mu opioid receptor over the δ receptor (K_i=132.50 nM) and the κ receptor (K_i=26.45 nM). NAQ can be used for the research of opioid withdrawal or dependence.

HY-G0021S

N-Desmethylclozapine-d₈	Agonist
N-Desmethylclozapine-d₈ is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist[1][2].

HY-P3870

DALDA	Agonist
DALDA is a potent and highly selective μ-opioid receptor agonist with a K_i of 1.69 nM. DALDA shows antinociceptive and respiratory effects.

HY-118949

LY255582	Antagonist
LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (K_i: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity.

HY-P3546

[DPen2, Pen5] Enkephalin	Agonist
[DPen2, Pen5] Enkephalin is a δ-opioid receptor selective analog of [Leu5]-Enkephalin (HY-P0288).

Name
Email *

	Sorry, but the email address you supplied was invalid.